Work Here?
Overview
Brooklyn Health builds Willis, an electronic Clinical Outcome Assessment (eCOA) platform for CNS clinical trials that uses AI and digital phenotyping to analyze clinical interviews by measuring spoken words, facial expressions, body language, and vocal tone to track symptoms over time. The platform is organized into OpenWillis (open-source phenotyping methods), WillisPipeline (converts behavioral data into clinical measures), and WillisAPI (integration with other digital health tools). This setup helps pharma teams use validated, standardized measures instead of creating their own, enabling more objective trial data. The company aims to improve the accuracy of treatment evaluation in CNS trials and reduce trial failures by better separating drug effects from placebo.
About Brooklyn Health
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Seed
Total Funding
$6.5M
Headquarters
New York City, New York
Founded
2023
Simplify's Take
What believers are saying
- FDA 2025 guidance endorses AI eCOA platforms, accelerating Willis validation.
- JMIR April 2026 validates phenotyping, reducing placebo response by 25%.
- Pharma AI biomarker adoption surged 40% in Q1 2026 with Boehringer expansion.
What critics are saying
- Bristol Myers Squibb builds proprietary phenotyping platforms within 18 months.
- OpenWillis enables CROs to replicate functionality without fees in 12 months.
- FDA rejects Willis endpoints if validation fails in 12 months.
What makes Brooklyn Health unique
- Willis platform automates clinical interviews using AI for facial expressions and vocal tone.
- OpenWillis provides open-source digital phenotyping library for validated measures.
- WillisAPI integrates with pharma platforms like Bristol Myers Squibb and Boehringer Ingelheim.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$6.5M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↑ 5%2 year growth
↓ -9%HealthX Ventures has invested in Brooklyn Health, which uses AI-powered tools to improve mental health measurement in CNS clinical trials. Their platform offers objective, scalable assessments, enhancing trial outcomes and reducing placebo effects. Led by Dr. Anzar Abbas, Brooklyn Health's technology is gaining traction with pharma companies, ensuring accurate patient selection and trial integrity. Their open-science approach fosters trust, aiming to bring more effective therapies to market.
Brooklyn Health, a neuroscience technology company secured $6.5M in seed funding to expand AI-powered precision for clinical trial endpoints.
Brooklyn Health has raised $6.5 million to enhance the reliability of mental health drug trials by standardizing the assessment of their effects. The company's technology aims to address the issue of unreliable effect measurements, which can lead to trial failures even when the drugs are effective. Brooklyn Health plans to share its code to further this initiative.
There are no jobs for Brooklyn Health right now.
Find jobs on Simplify and start your career today
About Brooklyn Health
Industries
Data & Analytics
Enterprise Software
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Seed
Total Funding
$6.5M
Headquarters
New York City, New York
Founded
2023
There are no jobs for Brooklyn Health right now.
Find jobs on Simplify and start your career today